Treatment of Mild Vascular Cognitive Impairment With Yangxue Qingnao Pill

1. Over 50 years old, under 85 years old, male and female, including 50 and 85 years old;

2. The patients agreed to participate in the trial and signed the informed consent.

3. The diagnostic criteria for vascular cognitive impairment without dementia are as follows:

1. There are risk factors of cerebrovascular disease or the existence of cerebrovascular disease;

2. The development of cognitive impairment was fluctuating;

3. Mild memory impairment or retention;

4. There is a causal relationship between cerebrovascular disease and cognitive impairment, and other diseases are excluded;

5. The activities of daily living remained normal;

6. According to the diagnostic criteria of mild cognitive impairment (MCI) developed by Xiao Shifu, the subjects' MMSE score was less than or equal to 26

1. The researchers considered that it was not suitable to be included in the study;

2. Known liver diseases of clinical significance, which may hinder patients from completing the test, and / or total bilirubin, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase are 1.5 times higher than the upper limit of normal value;

3. The patients with known clinically significant kidney disease may be prevented from completing the test, and / or the serum creatinine is higher than the normal range in the laboratory, and / or the blood urea nitrogen is 1.5 times higher than the normal range;

4. He had a history of acute cerebrovascular disease within 3 months;

5. At present, there is active epilepsy;

6. History of mental illness;

7. Peptic ulcer and gastrointestinal bleeding;

8. Any of the tested drugs was taken within 28 days before medication, which may cause cognitive changes and important organ damage.

9. Accompanied by unstable blood system and immune system diseases, is not in clinical remission.

10. Malignant tumor or intracranial tumor is known;

11. Those who had surgery within three months or had a history of trauma.

12. There are other advanced, serious or unstable diseases, which affect the evaluation of its efficacy and safety;